Study Details To investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy
Protocol Number CLNP023D12201
Phase II
Therapeutic Area Nephrology
Subject Types With Medical Condition
Indication Idiopathic membranous nephropathy
Principal Investigator A/Prof Jimmy Teo Boon Wee
Investigator Product / Device LNP023
Sponsor Novartis Singapore Pte Ltd
Top